Kudo S, Chuang V P, Wallace S, Mir S, Bechtel W, Carrasco C H
Cardiovasc Intervent Radiol. 1985;8(1):1-7. doi: 10.1007/BF02552632.
Arterial thrombolysis was successfully accomplished in 15 of 18 (83%) cancer patients by the continuous intraarterial transcatheter administration of streptokinase (70 units/kg/h or 5000 u/h and/or urokinase (400-500 u/kg/h) over 24-96 h. In 16 of these patients, the arterial thrombosis was a complication of transcatheter infusion of chemotherapeutic agents or embolization therapy. A combination of streptokinase, urokinase and heparin (10,000-25,000 U/day) was utilized without significant side effect and was effective in all 8 patients receiving treatment. Creating a tunnel through the clot, daily monitoring of the catheter with repositioning when necessary, and adjusting the type and dose of thrombolytic agent aided the therapeutic management.
通过持续经动脉导管给予链激酶(70单位/千克/小时或5000单位/小时)和/或尿激酶(400 - 500单位/千克/小时),在24至96小时内,18例癌症患者中有15例(83%)成功完成动脉溶栓。在这些患者中,有16例动脉血栓形成是化疗药物经导管输注或栓塞治疗的并发症。使用链激酶、尿激酶和肝素(10,000 - 25,000单位/天)联合治疗,无明显副作用,对所有8例接受治疗的患者均有效。通过血栓形成通道、每日监测导管并在必要时重新定位,以及调整溶栓剂的类型和剂量有助于治疗管理。